These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 11985384)
21. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353 [TBL] [Abstract][Full Text] [Related]
22. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223 [TBL] [Abstract][Full Text] [Related]
23. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P; Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768 [TBL] [Abstract][Full Text] [Related]
24. Functional system scores provide a window into disease activity occurring during a multiple sclerosis treatment trial. Scott TF; You X; Foulds P Neurol Res; 2011 Jun; 33(5):549-52. PubMed ID: 21669126 [TBL] [Abstract][Full Text] [Related]
25. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Rudick RA; Cutter GR; Baier M; Weinstock-Guttman B; Mass MK; Fisher E; Miller DM; Sandrock AW Mult Scler; 2005 Dec; 11(6):626-34. PubMed ID: 16323317 [TBL] [Abstract][Full Text] [Related]
26. Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study. Fernández O; Arbizu T; Izquierdo G; Martínez-Yélamos A; Gata JM; Luque G; de Ramón E Acta Neurol Scand; 2003 Jan; 107(1):7-11. PubMed ID: 12542507 [TBL] [Abstract][Full Text] [Related]
27. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
28. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. Milanese C; La Mantia L; Palumbo R; Martinelli V; Murialdo A; Zaffaroni M; Caputo D; Capra R; Bergamaschi R; J Neurol Neurosurg Psychiatry; 2003 Dec; 74(12):1689-92. PubMed ID: 14638892 [TBL] [Abstract][Full Text] [Related]
29. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959 [TBL] [Abstract][Full Text] [Related]
30. Use of the FIM instrument in a trial of intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis. Granger CV; Wende K; Brownscheidle CM Am J Phys Med Rehabil; 2003 Jun; 82(6):427-36. PubMed ID: 12820784 [TBL] [Abstract][Full Text] [Related]
31. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis. Pakdaman H; Abbasi M; Gharagozli K; Ashrafi F; Delavar Kasmaei H; Amini Harandi A Neurol Sci; 2018 Dec; 39(12):2107-2113. PubMed ID: 30171370 [TBL] [Abstract][Full Text] [Related]
32. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S; Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883 [TBL] [Abstract][Full Text] [Related]